| Ticker | ALXO |
|---|---|
| ISIN | US00166B1052 |
| Sector | Atención sanitaria |
| Industria | Biotechnology |
| Mercado | NASDAQ |
| Capitalización | $92.186.225 |
| Beta | 0,5 |
| Sitio web | https://www.alxoncology.com |
| CEO | Jason W. Lettmann |
| Fecha de IPO | 17/07/2020 |
| País | US |
| Dirección | 323 Allerton Avenue, South San Francisco, CA, 94080 |
| Volumen | 555.746 |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor recepto...
El precio actual de ALX Oncology Holdings Inc. (ALXO) es de 1,70, con una variación del 7,59%.
ALX Oncology Holdings Inc. opera en el sector Healthcare, industria Biotechnology.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones